Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JAGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsJaguar Health converts 7.92 preferred shares to 64,668 common shares in two Streeterville deals
Filed June 2, 2026 · Period ending June 1, 2026 · ~1 min read
Key Changes
-
medium
Company exchanged 7.92 shares of Series Q Preferred Stock for 64,668 common shares with Streeterville in two transactions (May 26 and June 1), diluting existing common shareholders while simplifying capital structure.
Item 3.02 verify on EDGAR → -
medium
Exchanges leave approximately 400 of the original 408 Series Q Preferred shares issued to Streeterville on May 19 still outstanding, suggesting potential for additional conversions.
Item 3.02 verify on EDGAR → -
low
Common shares issued under Section 3(a)(9) exemption without SEC registration, a standard exemption for exchanges with existing security holders.
Item 3.02 verify on EDGAR → -
low
Annual stockholder meeting adjourned again to June 8 after company filed supplemental proxy materials on May 29, giving shareholders more time to review before voting.
Item 5.03 view on EDGAR →
Summary
Jaguar Health completed two preferred-to-common stock exchanges with Streeterville Capital in the span of one week, converting a total of 7.92 Series Q Preferred shares into 64,668 common shares. The first exchange on May 26 converted 3.72 preferred shares for 31,958 common shares, followed by a second exchange on June 1 converting 4.2 preferred shares for 32,710 common shares.
Both sets of preferred shares were cancelled after the exchanges. These transactions represent less than 2% of the 408 Series Q Preferred shares originally issued to Streeterville on May 19, leaving roughly 400 shares still outstanding. For common shareholders, these exchanges increase the share count and create dilution, though the impact depends on the total shares outstanding.
The rapid succession of two exchanges within a week may signal ongoing negotiations to restructure the company's capital stack. Investors should watch whether additional preferred-to-common conversions follow, as the bulk of the Series Q Preferred remains outstanding. The company also adjourned its annual meeting to June 8 after filing supplemental proxy materials, suggesting potential changes to proposals that warranted additional shareholder review time.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 26, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 31,958 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) to Streeterville in exchange for an aggregate of 3.72 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”). Upon completion of such exchange, the First Exchanged Preferred Shares were cancelled and retired.
The company exchanged 3.72 shares of Series Q Preferred Stock for 31,958 common shares with Streeterville on May 26, 2026. The preferred shares were cancelled after the exchange. This transaction reduces preferred equity and increases common share count, diluting existing common shareholders.
Added in current filing · verify on EDGAR →
On June 1, 2026, the Company entered into another privately negotiated exchange agreement with Streeterville (the “Second Exchange Agreement”), pursuant to which the Company issued 32,710 shares (the “Second Exchange Shares”) of Common Stock to Streeterville in exchange for an aggregate of 4.2 outstanding shares of Series Q Preferred Stock held by Streeterville (the “Second Exchanged Preferred Shares”). Upon completion of such exchange, the Second Exchanged Preferred Shares were cancelled and retired.
The company exchanged 4.2 shares of Series Q Preferred Stock for 32,710 common shares with Streeterville on June 1, 2026. The preferred shares were cancelled after the exchange. This is the second such transaction in a week, further simplifying the capital structure while diluting common shareholders.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
As previously disclosed, on May 19, 2026, Jaguar Health, Inc. (the “Company”) sold and issued to Streeterville Capital, LLC (“Streeterville”) an aggregate of 408 shares of Series Q Perpetual Preferred Stock (the “Series Q Preferred Stock”) in two privately negotiated exchange transactions.
The company originally issued 408 shares of Series Q Preferred Stock to Streeterville on May 19, 2026. The two subsequent exchanges converted 7.92 of those 408 shares back to common stock, leaving approximately 400 shares of Series Q still outstanding with Streeterville.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Jaguar Health issued unregistered equity securities in exchange transactions under Section 3(a)(9) exemption.
Added in current filing · verify on EDGAR →
The First Exchange Shares and Second Exchange Shares were issued in reliance on the exemption from registration provided under Section 3(a) (9) of the Securities Act of 1933, as amended (the “Securities Act”).
The company issued two classes of exchange shares without SEC registration, using the Section 3(a)(9) exemption which typically applies to securities exchanges with existing shareholders. The filing references Item 1.01 for additional details about these exchange transactions, but that section is not included in the provided excerpt.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On June 2, 2026, the Company reconvened its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) that was adjourned on May 22, 2026. At the Annual Meeting, the Company announced that since it filed on May 29, 2026 a supplement (the “Supplement”) to the definitive proxy statement of the Annual Meeting on Schedule 14A, originally filed with the Securities and Exchange Commission (the “SEC”) on April 30, 2026 (as amended and supplemented, the “Proxy Statement”), to provide additional information to the stockholders regarding certain proposals in the Proxy Statement, the Company decided to further adjourn the Annual Meeting until Monday, June 8, 2026 at 8:30 a.m. Pacific Time to ensure that the stockholders have sufficient time to review and consider such additional information before voting.
The company reconvened its annual stockholder meeting on June 2, 2026, which had previously been adjourned on May 22, 2026. After filing supplemental proxy materials on May 29, 2026, management decided to adjourn the meeting again until June 8, 2026 to give stockholders additional time to review the new information before voting. The record date remains April 15, 2026, and stockholders who already voted do not need to take action unless they wish to change their vote.
Event · Item 9.01 — Financial Statements and Exhibits
Jaguar Health entered into two Streeterville Exchange Agreements on May 26 and June 1, 2026.
Added in current filing · verify on EDGAR →
Streeterville Exchange Agreement, dated May 26, 2026
The company executed two exchange agreements with Streeterville on May 26 and June 1, 2026. Exchange agreements typically involve converting existing debt or securities into different securities, often to restructure obligations or modify terms. Without the full exhibit text, the specific securities exchanged, conversion ratios, and financial impact remain unclear.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify